

Chromogenic Factor VIII Inhibitor Bethesda Profile,
Plasma

Patient ID SA00144160	Patient Name SAMPLEREPORT, TESTINGPATIENT	Birth Date 1987-12-28	Gender F	Age 33
Order Number SA00144160	Client Order Number SA00144160	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 14 Apr 2021 00:00		

Chromogenic FVIII Inhibitor Profile

Chromogenic FVIII Inhibitor Interp

MCR

IMPRESSION: Assays confirm presence of a specific inhibitor of factor VIII of 0.6 Bethesda Units.

COMMENTS: Decreased chromogenic factor VIII coagulant activity. The FVIII inhibitor titrating assay (Bethesda), performed after pre-analytical heat-inactivation of patient plasma and using bovine reagent based chromogenic FVIII reagents, confirms the presence of a specific inhibitor of coagulation factor VIII of 0.6 Bethesda Units.

Reviewed by

MCR

KATHLEEN MEYERS

Result Name	Value	Unit	Reference Value	Performing Site
 Chromogenic FVIII, P 	54.0	%	55.0–200.0	MCR
Assay discrepancy between chromogenic FVIII assay and one stage FVIII assay may potentially result in a missed diagnosis (or misclassification of severity) of mild/moderate hemophilia A. Serum and plasma specimens, either collected in EDTA or contaminated with heparin, will falsely lower FVIII levels.				
 Chromogenic FVIII Inhibitor Titer,P 	0.6	BU	≤0.5	① MCR

Received: 14 Apr 2021 13:23

Reported: 14 Apr 2021 13:26

Laboratory Notes

- ① This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Report Status: Final

Printed 10 May 2021

Received and reported dates and times are reported in US Central Time.

Page 1 of 1